nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—Paranoia—Carmustine—lymphatic system cancer	0.0195	0.0195	CcSEcCtD
Scopolamine—Abdominal cramps—Vincristine—lymphatic system cancer	0.0188	0.0188	CcSEcCtD
Scopolamine—Speech disorder—Carmustine—lymphatic system cancer	0.0155	0.0155	CcSEcCtD
Scopolamine—Dysphagia—Fludarabine—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Scopolamine—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Scopolamine—Sweating—Teniposide—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Scopolamine—Vertigo—Mechlorethamine—lymphatic system cancer	0.0126	0.0126	CcSEcCtD
Scopolamine—Disorientation—Bleomycin—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Scopolamine—Dysuria—Fludarabine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Scopolamine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Scopolamine—Flushing—Teniposide—lymphatic system cancer	0.011	0.011	CcSEcCtD
Scopolamine—Arrhythmia—Teniposide—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Scopolamine—Pharyngitis—Fludarabine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Scopolamine—Amnesia—Carmustine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Scopolamine—Visual impairment—Fludarabine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Scopolamine—Agitation—Teniposide—lymphatic system cancer	0.00951	0.00951	CcSEcCtD
Scopolamine—Arrhythmia—Fludarabine—lymphatic system cancer	0.00933	0.00933	CcSEcCtD
Scopolamine—Urinary retention—Vincristine—lymphatic system cancer	0.00878	0.00878	CcSEcCtD
Scopolamine—Muscular weakness—Carmustine—lymphatic system cancer	0.00853	0.00853	CcSEcCtD
Scopolamine—Confusional state—Teniposide—lymphatic system cancer	0.00852	0.00852	CcSEcCtD
Scopolamine—Oedema—Teniposide—lymphatic system cancer	0.00845	0.00845	CcSEcCtD
Scopolamine—Agitation—Fludarabine—lymphatic system cancer	0.00836	0.00836	CcSEcCtD
Scopolamine—Dysphagia—Carmustine—lymphatic system cancer	0.00836	0.00836	CcSEcCtD
Scopolamine—Tachycardia—Teniposide—lymphatic system cancer	0.00824	0.00824	CcSEcCtD
Scopolamine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00817	0.00817	CcSEcCtD
Scopolamine—Muscular weakness—Vincristine—lymphatic system cancer	0.00814	0.00814	CcSEcCtD
Scopolamine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00811	0.00811	CcSEcCtD
Scopolamine—Hypotension—Teniposide—lymphatic system cancer	0.00789	0.00789	CcSEcCtD
Scopolamine—Confusional state—Fludarabine—lymphatic system cancer	0.00749	0.00749	CcSEcCtD
Scopolamine—Dysuria—Vincristine—lymphatic system cancer	0.00746	0.00746	CcSEcCtD
Scopolamine—Oedema—Fludarabine—lymphatic system cancer	0.00742	0.00742	CcSEcCtD
Scopolamine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Scopolamine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00728	0.00728	CcSEcCtD
Scopolamine—Rash—Mechlorethamine—lymphatic system cancer	0.00722	0.00722	CcSEcCtD
Scopolamine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00722	0.00722	CcSEcCtD
Scopolamine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00718	0.00718	CcSEcCtD
Scopolamine—Speech disorder—Methotrexate—lymphatic system cancer	0.00717	0.00717	CcSEcCtD
Scopolamine—Flushing—Bleomycin—lymphatic system cancer	0.00711	0.00711	CcSEcCtD
Scopolamine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00696	0.00696	CcSEcCtD
Scopolamine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Scopolamine—Sweating—Vincristine—lymphatic system cancer	0.00682	0.00682	CcSEcCtD
Scopolamine—Nausea—Mechlorethamine—lymphatic system cancer	0.00681	0.00681	CcSEcCtD
Scopolamine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00673	0.00673	CcSEcCtD
Scopolamine—Abdominal pain—Teniposide—lymphatic system cancer	0.00668	0.00668	CcSEcCtD
Scopolamine—Body temperature increased—Teniposide—lymphatic system cancer	0.00668	0.00668	CcSEcCtD
Scopolamine—Erythema—Bleomycin—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Scopolamine—Hallucination—Carmustine—lymphatic system cancer	0.00665	0.00665	CcSEcCtD
Scopolamine—Sweating—Mitoxantrone—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Scopolamine—Visual impairment—Carmustine—lymphatic system cancer	0.00644	0.00644	CcSEcCtD
Scopolamine—Fatigue—Fludarabine—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Scopolamine—Hallucination—Vincristine—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Scopolamine—Constipation—Fludarabine—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Scopolamine—Pain—Fludarabine—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Scopolamine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Scopolamine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.0063	0.0063	CcSEcCtD
Scopolamine—Urethral disorder—Vincristine—lymphatic system cancer	0.00626	0.00626	CcSEcCtD
Scopolamine—Eye disorder—Carmustine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Scopolamine—Flushing—Carmustine—lymphatic system cancer	0.00621	0.00621	CcSEcCtD
Scopolamine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00617	0.00617	CcSEcCtD
Scopolamine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Scopolamine—Asthenia—Teniposide—lymphatic system cancer	0.00606	0.00606	CcSEcCtD
Scopolamine—Pruritus—Teniposide—lymphatic system cancer	0.00598	0.00598	CcSEcCtD
Scopolamine—Arrhythmia—Carmustine—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Scopolamine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Scopolamine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Scopolamine—Mental disorder—Carmustine—lymphatic system cancer	0.00586	0.00586	CcSEcCtD
Scopolamine—Erythema—Carmustine—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Scopolamine—Mental disorder—Vincristine—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Scopolamine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Scopolamine—Confusional state—Bleomycin—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Scopolamine—Vision blurred—Carmustine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Scopolamine—Tremor—Carmustine—lymphatic system cancer	0.00545	0.00545	CcSEcCtD
Scopolamine—Oedema—Bleomycin—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Scopolamine—Erythema—Mitoxantrone—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Scopolamine—Vomiting—Teniposide—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Scopolamine—Agitation—Carmustine—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Scopolamine—Asthenia—Fludarabine—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Scopolamine—Rash—Teniposide—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Scopolamine—Dermatitis—Teniposide—lymphatic system cancer	0.00532	0.00532	CcSEcCtD
Scopolamine—Headache—Teniposide—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Scopolamine—Pruritus—Fludarabine—lymphatic system cancer	0.00525	0.00525	CcSEcCtD
Scopolamine—Agitation—Vincristine—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Scopolamine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Scopolamine—Hypotension—Bleomycin—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Scopolamine—Nausea—Teniposide—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Scopolamine—Vertigo—Vincristine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Scopolamine—Confusional state—Carmustine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Scopolamine—Oedema—Carmustine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Scopolamine—Vomiting—Fludarabine—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Scopolamine—Rash—Fludarabine—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Scopolamine—Dermatitis—Fludarabine—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Scopolamine—Pain—Bleomycin—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Scopolamine—Headache—Fludarabine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Scopolamine—Tachycardia—Carmustine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Scopolamine—Oedema—Vincristine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Scopolamine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Scopolamine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Scopolamine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Scopolamine—Hypotension—Carmustine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Scopolamine—Oedema—Mitoxantrone—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Scopolamine—Nausea—Fludarabine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Scopolamine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Scopolamine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Scopolamine—Body temperature increased—Bleomycin—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Scopolamine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Scopolamine—Irritability—Methotrexate—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Scopolamine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Scopolamine—Hypotension—Vincristine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Scopolamine—Somnolence—Carmustine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Scopolamine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Scopolamine—Pain—Carmustine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Scopolamine—Constipation—Carmustine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Scopolamine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Scopolamine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Scopolamine—Fatigue—Vincristine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Scopolamine—Asthenia—Bleomycin—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Scopolamine—Pain—Vincristine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Scopolamine—Constipation—Vincristine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Scopolamine—Pruritus—Bleomycin—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Scopolamine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Scopolamine—Constipation—Mitoxantrone—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Scopolamine—Pain—Mitoxantrone—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Scopolamine—Body temperature increased—Carmustine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Scopolamine—Abdominal pain—Carmustine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Scopolamine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Scopolamine—Dysuria—Methotrexate—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Scopolamine—Abdominal pain—Vincristine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Scopolamine—Body temperature increased—Vincristine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Scopolamine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Scopolamine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Scopolamine—Vomiting—Bleomycin—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Scopolamine—Drowsiness—Methotrexate—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Scopolamine—Rash—Bleomycin—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Scopolamine—Dermatitis—Bleomycin—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Scopolamine—Asthenia—Carmustine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Scopolamine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Scopolamine—Sweating—Methotrexate—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Scopolamine—Asthenia—Vincristine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Scopolamine—Nausea—Bleomycin—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Scopolamine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Scopolamine—Dizziness—Carmustine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Scopolamine—Pharyngitis—Methotrexate—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Scopolamine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Scopolamine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Scopolamine—Vomiting—Carmustine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Scopolamine—Dizziness—Vincristine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Scopolamine—Rash—Carmustine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Scopolamine—Dermatitis—Carmustine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Scopolamine—Visual impairment—Methotrexate—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Scopolamine—Headache—Carmustine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Scopolamine—Eye disorder—Methotrexate—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Scopolamine—Vomiting—Vincristine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Scopolamine—Rash—Vincristine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Scopolamine—Dermatitis—Vincristine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Scopolamine—Headache—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Scopolamine—Nausea—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Scopolamine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Scopolamine—Rash—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Scopolamine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Scopolamine—Headache—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Scopolamine—Mental disorder—Methotrexate—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Scopolamine—Erythema—Methotrexate—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Scopolamine—Nausea—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Scopolamine—Nausea—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Scopolamine—Vision blurred—Methotrexate—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Scopolamine—Vertigo—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Scopolamine—Confusional state—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Scopolamine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Scopolamine—Skin disorder—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Scopolamine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Scopolamine—Hypotension—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Scopolamine—Somnolence—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Scopolamine—Fatigue—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Scopolamine—Pain—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Scopolamine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Scopolamine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Scopolamine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Scopolamine—Asthenia—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Scopolamine—Pruritus—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Scopolamine—Dizziness—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Scopolamine—Vomiting—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Scopolamine—Rash—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Scopolamine—Dermatitis—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Scopolamine—Headache—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Scopolamine—Nausea—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
